Ching-Ting Tan

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Transcription Factor

Natural Killer Cells

Top Venues

The Journal of pathology

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Yi-Mei Lee, Yu-Hsin Chen, Da-Liang Ou, Chia-Lang Hsu, Jia-Hua Liu, Jenq-Yuh Ko, Mickey C-T Hu, Ching-Ting Tan
SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. The Journal of pathology 259 (4) (2023)
Yi-Mei Lee, Yu-Hsin Chen, Da-Liang Ou, Chia-Lang Hsu, Jia-Hua Liu, Jenq-Yuh Ko, Mickey C-T Hu, Ching-Ting Tan
SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. The Journal of pathology 259 (4) (2023)
Yi-Mei Lee, Yu-Hsin Chen, Da-Liang Ou, Chia-Lang Hsu, Jia-Hua Liu, Jenq-Yuh Ko, Mickey C-T Hu, Ching-Ting Tan
SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. The Journal of pathology 259 (4) (2023)
Yi-Mei Lee, Yu-Hsin Chen, Da-Liang Ou, Chia-Lang Hsu, Jia-Hua Liu, Jenq-Yuh Ko, Mickey C-T Hu, Ching-Ting Tan
SN-38, an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma. The Journal of pathology (2023)
Yi-Mei Lee, Yu-Hsin Chen, Da-Liang Ou, Chia-Lang Hsu, Jia-Hua Liu, Jenq-Yuh Ko, Mickey C-T Hu, Ching-Ting Tan
SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. The Journal of pathology (2023)
Yi-Mei Lee, Yu-Hsin Chen, Da-Liang Ou, Chia-Lang Hsu, Jia-Hua Liu, Jenq-Yuh Ko, Mickey C-T Hu, Ching-Ting Tan
SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. The Journal of pathology 259 (4) (2023)
Yi-Mei Lee, Chia-Lang Hsu, Yu-Hsin Chen, Da-Liang Ou, Chiun Hsu, Ching-Ting Tan
Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy. Cancer immunology research (2023)